Royalty Pharma will acquire Zealand Pharma's royalty rights and potential commercial milestones worth $85 million tied to Lyxumia/Adlyxin, or lixisenatide, and Soliqua/Suliqua, or insulin glargine and lixisenatide injection, both indicated to treat diabetes type 2. Royalty will pay $205 million in the deal.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.